Back to Search
Start Over
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
- Source :
- Journal of Clinical Medicine, Journal of Clinical Medicine, Vol 9, Iss 3692, p 3692 (2020), Volume 9, Issue 11
- Publication Year :
- 2020
-
Abstract
- Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported&mdash<br />281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months&mdash<br />65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.
- Subjects :
- medicine.medical_specialty
medicine.drug_class
lcsh:Medicine
Tyrosine-kinase inhibitor
Article
03 medical and health sciences
0302 clinical medicine
chronic myeloid leukemia
hemic and lymphatic diseases
Internal medicine
Retrospective analysis
Medicine
In patient
treatment-free remission
molecular monitoring
business.industry
lcsh:R
Myeloid leukemia
General Medicine
Discontinuation
030220 oncology & carcinogenesis
Major Molecular Response
Cohort
business
Off Treatment
030215 immunology
Subjects
Details
- ISSN :
- 20770383
- Volume :
- 9
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of clinical medicine
- Accession number :
- edsair.doi.dedup.....6acdd79a16dcb802ab63d02912e6cfc8